Bayer Pharmaceuticals accelerates innovations for patients
LifeProNow
MARCH 27, 2023
Kerendia is already approved in major markets in chronic kidney disease (CKD) associated with type 2 diabetes. The estimated compounded annual growth rate is more than 26 percent reaching $1.36 Bayer works on leveraging all the possibilities of the technologies while fully integrating all regulatory and bioethical requirements.”
130 
Let's personalize your content